Navigation Links
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Date:7/17/2008

ting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. In endometriosis, AIs act primarily by inhibiting local estradiol production inside the endometrial lesions. AIs are currently used for the chronic treatment of estrogen-dependent tumors in postmenopausal women and are being investigated in a variety of women's health conditions. Meditrina holds the exclusive worldwide rights to patent applications covering the use of AIs in gynecologic indications, including for endometrial thinning prior to hysteroscopic procedures.

About Meditrina Pharmaceuticals, Inc.

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs. By identifying, leveraging and repurposing marketed products and product candidates at advanced stages of development, Meditrina's novel therapies have the potential to significantly alter the way these women's health conditions are treated. For more information about Meditrina Pharmaceuticals, please visit http://www.meditrina.com .

Meditrina Pharmaceuticals, Inc. Forward-Looking Statement Disclaimer

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, s
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
4. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
5. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
9. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... DIEGO , May 4, 2015 ... oncology company focused on the clinical development of ... data showing mitochondria-specific effects of the Company,s investigational ... enhanced anti-tumor activity when combined with a tyrosine-kinase ... found ME-344 to be a potent inhibitor of ...
(Date:5/4/2015)... the cuvette manufacturing world, opened their doors to the public in early 2015.  In ... scientists amazing support for their spectroscopy needs.  ... ... ... In mid-2014 Simcha Woitovich ...
(Date:5/4/2015)... May 4, 2015 Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... financial results for quarter ending March 31, 2015 ... and will host a conference call that day ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... of Kit Check as a finalist for the EY ... Washington Region. The awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ... finalist by a panel of independent judges. Award ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... in Columbia, South Carolina. Fans of Paul McCartney ... There” tour which originally kicked off in 2013. The most ... and the legendary performer recently announced that he would be ... on June 21st, in Charlottesville, VA at John Paul Jones ...
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... new, 13,700 square foot facility scheduled to open in ... only provide fertility treatment and services for the center’s ... educational events to a number of local and international ... to their current Carmel Valley/Del Mar location and will ...
(Date:5/4/2015)... Rafael, CA (PRWEB) May 04, 2015 Unlike some ... foremost on imparting knowledge. The goal is to educate first ... the classroom. This ensures that the young runners are building ... careers. A few of the topics covered include Effort Based ... fast as I used to be? This is not a ...
(Date:5/4/2015)... May 04, 2015 Sylvia Hawthorn-Deppen shared her ... that it would remind others in similar situations that they ... from Chronic Pain and Discovery of New Energy” (published by ... new audience via a renewed press campaign. , “I have ... debilitating pain ,” Hawthorn-Deppen says. “As an adolescent I got ...
Breaking Medicine News(10 mins):Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2
... Nov. 21 Attorneys representing consumers and,third-party payers ... healthcare services giant McKesson (NYSE: MCK ... price of more than 400 prescription drugs by,manipulating ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ...
... 21 DATATRAK,International, Inc. (Nasdaq: DATA ... eClinical solutions for the clinical trials industry, today ... Corporation, has placed its first,self-designed project using the ... trial. The successful rollout of this first,independently ...
... VICL ) today announced a strategic restructuring ... the company,s total workforce,and accelerated closure of a research ... employees and expects to reduce future,net losses and cash ... The restructuring is designed to ...
... to a relationship between erectile dysfunction and prostate enlargement. Because of ... to increase the treatment of BPH in men. The focus of ... (ED). Dr. Eid will continue with ED treatments while building his ... ...
... prestigious "Super Dentist" award given to elite dentists in Texas. Dr. ... in the area of Cosmetic Dentistry. , ... Austin, ... Smiles was recently nominated as a "Texas Monthly Super Dentist" ...
... that timing is everything, and that certainly appears to be ... before the height of cold and flu season have a ... any other time of year, according to new research. ... more than 95,000 children and their mothers in Tennessee to ...
Cached Medicine News:Health News:Hagens Berman Sobol Shapiro: McKesson Settles RICO Lawsuit for $350 Million 2Health News:Hagens Berman Sobol Shapiro: McKesson Settles RICO Lawsuit for $350 Million 3Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 2Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 3Health News:Vical Announces Strategic Restructuring and Staff Reduction 2Health News:Vical Announces Strategic Restructuring and Staff Reduction 3Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 2Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 3Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 4Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Fall babies: Born to wheeze? 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: